Seattle Genetics is the premier firm that focuses on developing novel antibody-drug conjugates (ADC). ADCs are improved antibodies designed to facilitate the targeting capability of monoclonal antibodies by attaching cell-killing agents to them. The company is created on a solid basis of scientific research, commitment to addressing unmet medical needs of patients, and developing high-quality antibody-based medications.
Engineered monoclonal antibodies have been used to offer therapeutic benefits to patients with cancer, autoimmune disorders, and other complex medical conditions. Early antibody-based medication changed the approach of treating cancer by targeting cancerous cells and minimizing damage to healthy tissues. This led to perfect therapies that could be blended with chemotherapy to enhance patient results without increasing the amount of toxicities.
Although engineered antibodies have offered clinical benefit in numerous disease indications, most antibodies do not possess enough intrinsic antitumor activity to be utilized as therapeutics. Seattle Genetics has designed a proprietary, world-class technology that has revolutionized antibody-based therapies. Its ADC technology incorporates the specificity nature of engineered antibodies with the powerful cell-killing properties of chemotherapy.
ADCETRIS, first FDA-approved ADC
ADCETRIS is an ADC produced by Settle Genetics, and in partnership with Takeda Pharmaceutical Company, the drug is available for purchase in 65 nations, including the U.S. Japan, Canada, and EU’s member countries
Dr. Clay B. Siegall
Dr. Clay B. Siegall is a co-founder of Settle Genetics and a trained scientist. Under his gifted leadership, the firm has developed a diverse pipeline of therapies that are antibody based. These therapies meet the unmet demands and desires of cancer patients. Dr. Siegall serves as Board of Directors’ Chairman, President, and CEO of Seattle Genetics. He guided the company in the production of its first commercialized drug called ADCETRIS.
Dr. Siegall has been in charge of numerous capital raising activities of Settle Genetics. He has managed to raise over $675 million in both public as well as private funding. The IPO in 2001 generated a significant amount of funds for the company. Before launching Settle Genetics, Dr. Siegall held several research positions in institutions such as Bristol-Myers Squibb Pharmaceutical Research Institute (1991-1997), and the National Institutes of health, National Cancer Institute between 1988 and 1991.
Learn more here: